Search the Newsreel

Harvard Bioscience (NASDAQ: HBIO) grows Q2 sales but faces higher debt costs

Harvard Bioscience (NASDAQ: HBIO) reported an 11.1% increase in Q2 2026 revenue, reaching $22.7 million, primarily driven by strong sales to CROs in the Americas and distributors in Asia-Pacific. Despite revenue growth and ongoing cost-saving initiatives like "Project Viking," the company posted a net …

HARVARD BIOSCIENCE INC 2026: Revenue $22.73M, EPS ($0.64) — 10-Q Summary

HARVARD BIOSCIENCE INC (HBIO) reported its second-quarter 2026 results, showing an 11.1% year-over-year revenue increase to $22.73M. Despite this growth, the company recorded a net loss of ($2.91M) and a diluted loss per share of ($0.64). The revenue growth was primarily driven by increased …

The Options Market Says Marvell Stock Could Halve Or More Than Double

The options market for Marvell Technology (MRVL) stock indicates a wide potential trading range over the next thirteen months, from $90 to $492, suggesting it could more than double or fall by over half. This wide band reflects the stock's historical volatility and its …

Arvinas (ARVN) Q2 2026 Earnings Call Transcript

Harvard Bioscience targets 3% to 5% full-year 2026 revenue growth as CMT and China mix shifts gross margin to 57% to 59%

Earnings Call Insights: Harvard Bioscience (HBIO) Q2 2026 MANAGEMENT VIEW * "That disciplined focus and execution helped us deliver strong second quarter performance, highlighted by double-digit revenue growth across our CMT and preclinical portfolios and solid operational execution that reinforced our confidence in raising …

Marvell Could Be Next Winner in Microsoft AI Bet

This article first appeared on GuruFocus. Microsoft (NASDAQ:MSFT) is reportedly preparing to unveil its next-generation Maia 300 AI accelerator, a move Wedbush says could create a meaningful new opportunity for Marvell Technology (NASDAQ:MRVL) and Taiwan Semiconductor Manufacturing (NYSE:TSM). The key issue for investors is …

BioHarvest Sciences Inc. Common Stock Q2 2026 Earnings Call Summary

BioHarvest Sciences Inc. Common Stock Q2 2026 Earnings Call Summary - Moby Strategic Shift and Operational Performance Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 …

Can MRVL's NVDA Alliance Help it Challenge ALAB & AVGO?

Marvell Technology MRVL and NVIDIA NVDA are collaborating on advanced networking and optical technologies. Their expanded partnership includes silicon photonics and advanced optical interconnect solutions, areas in which MRVL has established capabilities in optical DSPs, silicon photonics and high-speed connectivity, and NVIDIA has NVLink …

Is Carvana Stock a Buy as Rapid Growth Tests Its Premium Valuation?

Carvana Co. CVNA is scaling quickly, with higher retail volumes, rising adjusted EBITDA and improving cash generation supporting its long-term growth case. The company is also expanding production capacity through ADESA as it targets a much larger share of the used-vehicle market. The trade-off …

BioHarvest Sciences Q2 Earnings Call Highlights

BioHarvest Sciences reported Q2 2026 revenue of $8.8 million, a 3.8% increase year-over-year, and highlighted its first CDMO agreement for a rare premium fragrance raw material, projected to generate $20-30 million in revenue during 2027-2028. The company narrowed its 2026 consolidated revenue guidance to …

BioHarvest Sciences: Secured first major CDMO contract and reaffirmed 2027 EBITDA breakeven despite revised 2026 guidance

BioHarvest Sciences reported Q2 2026 revenue of $8.8M, a 3.8% year-over-year increase, with a gross margin of 58% and a narrowed net loss of $3.7M. The company secured a significant CDMO fragrance contract, revised its 2026 revenue guidance to $37–$40M, and maintained its target …

Harvard Bioscience beats estimates, raises 2026 guidance

Harvard Bioscience Inc. (NASDAQ:HBIO) surpassed analyst expectations for its second-quarter 2026 results, reporting adjusted EPS of -$0.14 and revenue of $22.7 million, exceeding estimates. The company also raised its full-year 2026 revenue guidance to 3%-5% YoY growth, citing strong demand for its telemetry and …

Why Is Marvell Technology (MRVL) Investing $250 Million In India Now?

Marvell Technology (MRVL) announced a $250 million investment in India to expand its presence, roughly doubling its local headcount and growing facilities for semiconductor, AI, and cloud-related solutions. This move aims to deepen its role in India's semiconductor ecosystem through R&D, university collaboration, and …

Harvard Bioscience (HBIO) grows Q2 2026 sales but stays in loss

Harvard Bioscience (HBIO) reported an 11.1% increase in Q2 2026 revenue, reaching $22.7 million, with full-year revenue guidance raised to 3%-5% growth. Despite top-line expansion and improved gross margins, the company remains unprofitable, recording a Q2 2026 net loss of $2.9 million. Operating cash …

BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates

BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This …

Harvard Bioscience Q2 Revenue Rises 11 Percent to $22.7 Million

Harvard Bioscience (HBIO) reported an 11% increase in Q2 2026 revenue, reaching $22.7 million, despite a GAAP net loss of $2.9 million. The company also raised its full-year 2026 revenue guidance to 3% to 5% growth. Insider trading data shows multiple purchases of HBIO …

$BHST Q2 '26 Earnings Results & Recap

BioHarvest revenue rises 3.8% to $8.8 million

BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update

BioHarvest Sciences Inc. reported its second quarter 2026 financial results, securing its first CDMO Manufacturing Agreement for a 20-ton commercial production program of a rare botanical fragrance. The company reported $8.8 million in Q2 revenue, up 3.8% from Q2 2025, and is transitioning its …

BioHarvest Sciences shares surge 11% on major fragrance deal

BioHarvest Sciences Inc. reported second-quarter adjusted EPS of -$0.17 and revenue of $8.8 million, an increase of 3.8% year-over-year. The company's shares surged 11.43% after announcing a CDMO manufacturing agreement for a rare botanical fragrance, with limited production expected by early 2027. BioHarvest also …

Marine Harvest ASA (MHGVY) to Post Quarterly Earnings on Tuesday

BioHarvest Sciences GAAP EPS of -$0.17 misses by $0.05, revenue of $8.84M misses by $0.61M

* BioHarvest Sciences press release [https://seekingalpha.com/filing/309934017] (BHST [https://seekingalpha.com/symbol/BHST]): Q2 GAAP EPS of -$0.17 misses by $0.05. * Revenue of $8.84M (+3.8% Y/Y) misses by $0.61M. MORE ON BIOHARVEST SCIENCES * BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4904774-bioharvest-sciences-inc-bhst-q1-2026-earnings-call-transcript] * BioHarvest outlines 2026 …

BioHarvest Sciences (NASDAQ: BHST) grows H1 2026 revenue but flags going-concern risk

BioHarvest Sciences reported a modest increase in H1 2026 revenue to $17.344 million, with growth in both its Products and CDMO Services business units. Despite improved liquidity and a stronger balance sheet compared to the previous year, the company flagged substantial doubt about its …

Arvind SmartSpaces to address investors at Equirus India Growth Summit in Mumbai

Great Harvest Maeta Details Audit Fee Basis Ahead of RCHK Reappointment

Select Harvests (ASX:SHV) Shares Outperform in a Softer Sector Session

Harvard Bioscience Lifts 2026 Revenue Outlook After 11% Q2 Growth

Harvard Bioscience (HBIO) reported an 11% year-over-year revenue increase to $22.7 million in Q2 2026, leading them to raise their full-year 2026 revenue growth guidance to 3-5%. Despite a widened GAAP net loss, adjusted EBITDA saw growth, and the company provided Q3 2026 revenue …

Why Carvana (CVNA) Is Up 12.1% After Strong Q2 Earnings And Same-Day Delivery Expansion

Artemis Resources Secures Shareholder Backing for Capital-Raising Resolutions

Artemis Resources Reaffirms Existing Exploration Data and Carlow Resource Estimate

Enterprise value to EBITDA forward of Arvinas, Inc. – NASDAQ:ARVN

The article focuses on the enterprise value to EBITDA forward of Arvinas, Inc. (NASDAQ: ARVN), providing financial information and market data for the company. It appears to be a financial data page from TradingView, indicating that the market was closed with no trades at …

Marvell Technology (NASDAQ:MRVL) Shares Down 4.6% - Here's What Happened

Marvell Technology (NASDAQ:MRVL) shares dropped 4.6% to $208.56 on Monday, with trading volume lower than average. Despite the dip, analysts maintain a "Moderate Buy" consensus rating and an average price target of $245.45. The company recently reported strong quarterly revenue and matched EPS estimates, …

Marvell Technology Stock’s Multiple Leans On Profit From Below The Operating Line

Marvell Technology's stock (MRVL) has seen a 191% return over the last year but trades 31% below its 52-week high, with its high trailing price-to-earnings ratio of 76 largely supported by profit generated below the operating line rather than from core operations. While the …

Marvell Technology (MRVL) Commits $250 Million To India Chip R And D Growth

Marvell Technology (MRVL) plans to invest $250 million in India over the next three years to expand its advanced semiconductor R&D, aiming to double its India workforce and boost operations in Bangalore and Hyderabad. This investment will focus on AI, cloud, and data infrastructure …

Here's Why Marvell Technology (MRVL) Fell More Than Broader Market

Marvell Technology (MRVL) shares fell by 4.62%, underperforming the broader market and its sector. The chipmaker has seen a 7.25% loss over the past month. Investors are anticipating its Q3 2026 earnings report on August 27, 2026, with analysts expecting significant year-over-year growth in …

ARVN Maintains by Evercore ISI Group -- Price Target Lowered to $14.00

Evercore ISI Group has maintained an Outperform rating for Arvinas (ARVN) but lowered its price target from $19.00 to $14.00, reflecting a cautious outlook. Despite being significantly undervalued by GuruFocus's GF Value™ at $31.53 versus a current price of $8.95, the company faces financial …